Videos

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.

Shifting their focus to the REFLECT trial of lenvatinib in unresectable hepatocellular carcinoma, panelists consider use of tyrosine kinase inhibition in this setting.

A panel of experts review data from the IMbrave150 trial of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma and consider implications for treatment.

Theodore W. Laetsch, MD, discusses which trials were used for the retrospective study of the TRK inhibitor larotrectinib for the treatment of TRK-fusion cancers, including thyroid cancers.

A brief discussion on the potential role for adjuvant therapy in patients with hepatocellular carcinoma.

Taking recent clinical trial data into account, panelists consider the best treatment option for a patient with metastatic hepatocellular carcinoma.

In the context of metastatic hepatocellular carcinoma, panelists reflect on the value of multidisciplinary care at their institutions.

After introducing the third case, a patient with metastatic hepatocellular carcinoma, experts share their perspectives on the optimal diagnosis and work-up of advanced disease.

Tycel Phillips, MD, a clinical associate professor of hematology and medical oncology at the University of Michigan Health, discusses the mechanism of action of glofitamab in patients with mantle cell lymphoma.

Gurbakhash Kaur, MD, discusses the use of bispecific T-cell engagers as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

Darren R. Feldman, MD, discusses the standard of care for the treatment of testicular cancer.

Rebecca C. Arend, MD, discusses the key unmet needs in the treatment landscape for platinum-resistant ovarian cancer.

Cristiane D. Bergerot, PhD, discusses how financial toxicity associated with renal cell carcinoma is impacting oncologists and their patients.

William J. Gradishar, MD, discusses the design and results of a study of intravenous versus subcutaneous pertuzumab and trastuzumab in patients with HER2-positive breast cancer.

Clayton Lau, MD, advises primary care physicians and specialists on how to help address the rising prevalence of advanced-stage genitourinary cancers.

Andreana Holowatyj, PhD, MSCI, discusses the characteristics of appendiceal cancer and what differentiates it from colorectal cancer.

Toni Choueiri, MD, explains what led to the phase 3 COSMIC-313 clinical trial.

In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.

Dr. Bobby Liaw looks to the future of metastatic castration-sensitive prostate cancer treatment and provides some advice and clinical pearls.

A key opinion leader reviews how findings from the TITAN study affect treatment of metastatic castration-sensitive prostate cancer.

Bobby Liaw, MD, explains the potential treatment strategy for a prostate cancer case with low-volume metastatic disease.

A prostate cancer expert reviews the treatment approach in the presented case of biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease.

Dr. Bobby Liaw compares the available first-line therapy options for metastatic castration-sensitive prostate cancer and explains how to decide on a therapy.

An oncologist details the first-line therapy options for metastatic castration-sensitive prostate cancer.

Bobby Liaw, MD, presents the case of a 73-year-old man with biochemical recurrence of prostate cancer and metastatic castration-sensitive high-volume disease.

Chukwuemeka Ihemelandu, MD, explains the role of surgery in prolonging life and disease progression in patients with upper gastrointestinal cancers.

Alexandra Higgins,MD, discusses the association of hepatopulmonary syndrome with the long-term use of ado-trastuzumab emtansine.

Annelise Wilhite, MD, a gynecology oncology fellow at the University of South Alabama Health, discusses the difficulty in treating vulvar and vaginal melanomas.

Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.